<DOC>
	<DOC>NCT00988637</DOC>
	<brief_summary>This clinical trial will evaluate the efficacy and safety of Clobex® (clobetasol propionate) Spray 0.05% and Vectical™ (calcitriol) Ointment 3 µg/g over a four week period of use in one of two different regimens: 1. Vectical™ Ointment treatment, twice daily on weekdays (Mon - Fri) and Clobex® Spray treatment twice daily on weekends (Sat - Sun) for 28 days 2. Clobex® Spray once each morning and Vectical™ Ointment once each evening for 28 days</brief_summary>
	<brief_title>Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment &amp; Clobex® Spray for Moderate Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Male or female subjects aged 18 to 80 years inclusive Subjects with an Overall Disease Severity of 3 (moderate) Subjects with 3% 10% treatable BSA (Body Surface Area) excluding scalp, face, groin, axillae and/or other intertriginous areas For concurrent medications, type and dose must have been stable for at least 3 months prior to study entry and not expected to change during the study. Subjects receiving treatment with betablockers or lithium, whose dose has been stable for at lest 6 months and who have shown no worsening of their psoriasis, may be included in the study, at the discretion of the investigator Subjects with intakes of more than 2,000 IU/day (50 mcg/day) of vitamin D (tolerable upper intake level) and/or more than 1,000 mg/day of calcium Subjects whose psoriasis involves only the scalp, face, groin, axillae, and/or other intertriginous areas Subjects with a washout period for topical treatment less than 30 days (Any steroid containing medication, dovonex, anthralin, tar and/or UVB treatment) Subjects with a washout period for systemic treatment less than 12 weeks (corticosteroids, biologics and/or PUVA treatment; Examples of these therapies include, but are not limited to PUVA, Soriatane, Cyclosporine, Hydroxyurea, Mycophenolate mofetil, Sulfasalazine, Azathioprine, Alefacept, Efalizumab, Adalimumab, Etanercept, Infliximab, Rituximab, and Methotrexate) Subjects with nonplaque psoriasis or other related diseases not classified as plaque psoriasis Subjects who foresee intensive UV exposure during the study (mountain sports, UV radiation, sunbathing, etc.)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>